Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Shares Shorted: Short Interest Down 95.6% in September

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) was the recipient of a significant decrease in short interest during the month of September. As of September 30th, there was short interest totaling 19,900 shares, a decrease of 95.6% from the September 15th total of 451,633 shares. Based on an average daily trading volume, of 1,643,901 shares, the short-interest ratio is currently 0.0 days. Approximately 7.2% of the company’s stock are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings cut Scinai Immunotherapeutics from a “sell (e+)” rating to a “sell (e)” rating in a research report on Tuesday. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, Scinai Immunotherapeutics has a consensus rating of “Sell”.

Scinai Immunotherapeutics Price Performance

Shares of NASDAQ SCNI opened at $1.18 on Friday. The company has a current ratio of 1.56, a quick ratio of 1.35 and a debt-to-equity ratio of 0.05. The firm has a market cap of $837,800.00, a price-to-earnings ratio of -0.01 and a beta of 2.13. Scinai Immunotherapeutics has a 1-year low of $1.06 and a 1-year high of $15.65. The stock has a fifty day simple moving average of $2.06 and a two-hundred day simple moving average of $3.57.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Ltd. is an Israel-based clinical-stage biopharmaceutical company focused on developing immunotherapies for inflammatory and autoimmune diseases. The company’s research centers on NanoAb, its proprietary platform of single-domain antibodies designed to target disease-related proteins and potentially support localized treatment with reduced systemic exposure.

Scinai’s lead development program is SCNI-153, a NanoAb-based candidate targeting interleukin-17 (IL-17) for the treatment of plaque psoriasis.